Literature DB >> 3463976

Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.

C Nagler-Anderson, L A Bober, M E Robinson, G W Siskind, G J Thorbecke.   

Abstract

Although oral administration of protein antigens may lead to specific immunologic unresponsiveness, this method of immunoregulation has not been applied to models of autoimmune disease. Type II collagen-induced arthritis is an animal model of polyarthritis induced in susceptible mice and rats by immunization with type II collagen, a major component of cartilage. Intragastric administration of soluble type II collagen, prior to immunization with type II collagen in adjuvant, suppresses the incidence of collagen-induced arthritis. Administration of denatured type II collagen has no observable effect on the incidence or severity of the disease. The overall magnitude of the antibody response is not significantly reduced in collagen-fed mice as compared to controls. While the isotype distribution of the anti-collagen antibodies is similar in the two groups, there is a tendency toward reduced IgG2 responses in the collagen-fed mice.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463976      PMCID: PMC386734          DOI: 10.1073/pnas.83.19.7443

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  H-2-linked genetic control of antibody response to soluble calf skin collagen in mice.

Authors:  E Hahn; H Nowack; D GOTZE; R Timpl
Journal:  Eur J Immunol       Date:  1975-04       Impact factor: 5.532

2.  Suppressor T cells for IgE and IgG in Peyer's patches of mice made tolerant by the oral administration of ovalbumin.

Authors:  J Ngan; L S Kind
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

3.  The induction of tolerance to a soluble protein antigen by oral administration.

Authors:  H C Thomas; M V Parrott
Journal:  Immunology       Date:  1974-10       Impact factor: 7.397

4.  Capacity of mycobacterial wax D and its subfractions to induce adjuvant arthritis in rats.

Authors:  F D Wood; C M Pearson; A Tanaka
Journal:  Int Arch Allergy Appl Immunol       Date:  1969

5.  Specificity of the antibody response in inbred mice to bovine type I and type II collagen.

Authors:  H Nowack; E Hahn; R Timpl
Journal:  Immunology       Date:  1975-10       Impact factor: 7.397

6.  Immunologic suppression after oral administration of antigen. I. Specific suppressor cells formed in rat Peyer's patches after oral administration of sheep erythrocytes and their systemic migration.

Authors:  J A Mattingly; B H Waksman
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

7.  ELECTROPHORETIC SEPARATION AND PROPERTIES OF MOUSE ANTIHAPTEN ANTIBODIES INVOLVED IN PASSIVE CUTANEOUS ANAPHYLAXIS AND PASSIVE HEMOLYSIS.

Authors:  R S NUSSENZWEIG; C MERRYMAN; B BENACERRAF
Journal:  J Exp Med       Date:  1964-08-01       Impact factor: 14.307

8.  Enterically induced immunologic tolerance. I. Induction of suppressor T lymphoyctes by intragastric administration of soluble proteins.

Authors:  L K Richman; J M Chiller; W R Brown; D G Hanson; N M Vaz
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

9.  Assessing B cell diversification by antigen receptor and precursor cell analysis.

Authors:  N R Klinman; A R Pickard; N H Sigal; P J Gearhart; E S Metcalf; S K Pierce
Journal:  Ann Immunol (Paris)       Date:  1976 Jun-Jul

10.  Autoimmunity to type II collagen an experimental model of arthritis.

Authors:  D E Trentham; A S Townes; A H Kang
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

View more
  75 in total

Review 1.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Suppression of murine collagen-induced arthritis by nasal administration of collagen.

Authors:  L K Myers; J M Seyer; J M Stuart; A H Kang
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

3.  Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit.

Authors:  J B Sun; C Rask; T Olsson; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.

Authors:  H Fukaura; S C Kent; M J Pietrusewicz; S J Khoury; H L Weiner; D A Hafler
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

5.  Contribution of the spleen, lymph nodes and bone marrow to the antibody response in collagen-induced arthritis in the rat.

Authors:  J Rahman; N A Staines
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 6.  Clinical potential of antigen-specific therapies in type 1 diabetes.

Authors:  Ken T Coppieters; Birgit Sehested Hansen; Matthias G von Herrath
Journal:  Rev Diabet Stud       Date:  2012-12-28

7.  Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis.

Authors:  Inger Gjertsson; Karen L Laurie; James Devitt; Steven J Howe; Adrian J Thrasher; Rikard Holmdahl; Kenth Gustafsson
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

8.  Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice.

Authors:  T Bárdos; M Czipri; C Vermes; J Zhang; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  Identification and characterization of a major tolerogenic T-cell epitope of type II collagen that suppresses arthritis in B10.RIII mice.

Authors:  H Miyahara; L K Myers; E F Rosloniec; D D Brand; J M Seyer; J M Stuart; A H Kang
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 10.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.